
Index

A

- Acute pain,
 - definition, 269
 - intravenous patient-controlled analgesia, 269, 270
 - pathophysiology, 269
 - side effects of opioids, 270
 - treatment, 269, 270
- Addiction, *see* Buprenorphine; Levo- α -acetylmethadol; Methadone; Naltrexone; Self administration models; Tolerance, opioids
- Adenylyl cyclase, *see also* Cyclic AMP, assays,
 - cyclic AMP binding assay,
 - binding of unlabeled versus tritiated cyclic AMP, 33
 - cyclic AMP-dependent protein kinase preparation from bovine adrenals, 32, 36
 - hydroxyapatite removal of free cyclic AMP, 33, 36
 - separation of protein-bound from unbound cyclic AMP, 33
 - tritiated cyclic AMP preparation, 32
 - cyclic AMP concentration
 - determination in samples, 34
 - cyclic AMP-containing cell supernatant preparation,
 - cell suspension preparation, 31, 35
 - incubation conditions and
 - termination, 31, 32, 35, 36
 - materials, 30
 - principles, 29, 30

- opioid receptor signaling, 29
- signal transduction cascade, 29

Allodynia,

- cold allodynia measurement, 239
- dynamic mechanical allodynia measurement, 238
- static mechanical allodynia measurement, 237, 238, 241, 242

Alternative splicing, *see* Splice

- variants, opioid receptors

- γ -Aminobutyric acid (GABA), double immunohistochemical labeling with opioid receptors, 79, 80, 85–91

B

- Bioluminescence resonance energy transfer (BRET),
 - oligomerization assay for opioid receptors,
 - data collection, 167–169
 - data presentation, 169, 170
 - fusion protein constructs, 167, 178
 - materials, 160
 - signal optimization, 179, 180
 - transfection, 167
 - principles, 165–167, 177, 178
- BRET, *see* Bioluminescence resonance energy transfer
- Buprenorphine,
 - detoxification, 291, 293
 - development, 286
 - maintenance therapy, 288–290, 292, 293
 - pharmacology, 288

C

Calcium/calmodulin-dependent protein kinase II (CamKII),
assay,
incubation conditions and
 termination, 41, 45
materials, 39, 40
radioactivity counting, 42
tissue homogenization, 41, 44
opioid receptor signaling, 39
CamKII, *see* Calcium/calmodulin-
 dependent protein kinase II
cAMP, *see* Cyclic AMP
Cancer pain,
 definition, 274
 pathophysiology, 274
 treatment,
 adjuvant analgesia, 277
 administration routes, 277, 279
 nerve blocks, 279
 opioid types, 274–277
 palliative care, 279
 side effect management, 277
Chimeric opioid receptors,
 applications, 186, 187
 ligand-binding assays, 191, 192, 199,
 200
 materials for construction, 186
 polymerase chain reaction, 190, 198,
 199
 principles of construction, 187, 188
 transfection, 191, 199
Chinese hamster ovary cells, *see*
 Mammalian cell lines, opioid
 receptor expression
Chronic pain,
 adjuvant analgesia, 272, 273
 definition, 270
 pathophysiology, 270, 271
 treatment, 271, 272

Classical conditioning, *see* Place
 conditioning
Clonidine, detoxification therapy, 286,
 291
Cloning, *see* Complementary DNA
 library screening, opioid receptors
Complementary DNA library screening,
 opioid receptors,
 antibody screening, 10, 11, 13, 14
 materials, 4, 5
 nucleic acid probe screening,
 hybridization, 8
 in vivo excision, 9, 10, 13
 nylon membrane transfer of plaques,
 7, 12
 plasmid isolation containing positive
 colony inserts, 10, 13
 plating of library, 7, 12
 prehybridization, 8
 probe synthesis with polymerase
 chain reaction, 8, 13
 secondary and tertiary screening, 9,
 13
 titring of library,
 bacteria growth, 6, 12
 dilution of library, 6
 λ phage infection of host cells, 6
 washing, 9, 13
 overview, 3, 4
 polymerase chain reaction screening,
 amplification reaction, 11, 12, 14
 full-length cDNA amplification, 12,
 14, 15
 primer design, 11, 14
 product cloning and sequencing, 12, 14
 success factors, 3
Complementary DNA microarray,
 data analysis, 143
 principles, 142
 uses, 142, 143

- Conditioned place preference, *see* Place conditioning
- Cyclic AMP (cAMP), *see also*
Adenylyl cyclase,
opioid receptor heterodimer
signaling assay,
materials, 161
principles, 173, 181
radioimmunoassay, 174
opioid tolerance role, 224
signal transduction cascade, 29
- D**
- DD, *see* Differential display
- DEAE-dextran, *see* Mammalian cell lines, opioid receptor expression
- Dependence, *see* Buprenorphine; Levo- α -acetylmethadol; Methadone; Naltrexone; Self administration models; Tolerance, opioids
- Desensitization, opioid receptors in tolerance, 224
- Detoxification, *see* Buprenorphine; Methadone; Ultrarapid opiate detoxification
- Differential display (DD),
comparison with microarray
methods, 144
principles, 143
- E**
- Equianalgesic conversion table, 271
- F**
- Fentanyl, clinical use, 276
- G**
- GABA, *see* γ -Aminobutyric acid
- GAD, *see* Glutamic acid decarboxylase
- Gene arrays, *see* Complementary DNA microarray; Oligonucleotide array
- GIRKs, *see* G protein-activated inwardly rectifying potassium channels
- Glutamic acid decarboxylase (GAD),
double immunohistochemical
labeling with opioid receptors, 79,
80, 85–91
- Glyceraldehyde-3-phosphate
dehydrogenase (GPD), single-cell
reverse transcriptase-polymerase
chain reaction, 114
- GPD, *see* Glyceraldehyde-3-phosphate
dehydrogenase
- G protein-activated inwardly rectifying
potassium channels (GIRKs),
opioid receptor coupling, 53, 54, 157
structure, 53, 54
types, 53
weaver mouse,
behavioral analysis, 61
breeding, 60, 61
genotyping, 60
missense mutation, 59
overview, 54, 59
Xenopus oocyte expression,
collagenase treatment, 58
expression vectors, 57, 61
materials, 54–56
messenger RNA synthesis, 57
microinjection, 58
oocyte preparation, 58
rationale, 56, 57
voltage clamp recording, 58, 59, 61
- G protein-coupled receptor, structure,
185, 186
- GTP γ S, opioid receptor heterodimer
signaling assay,
agonist stimulation, 173, 174
materials, 161
membrane preparation, 173
principles, 173, 181

H

Hydromorphone, clinical use, 276

I

Immunohistochemistry, opioid receptors,
 antinociceptive brainstem circuits,
 79, 80
 double-labeling with GABA or glutamic acid decarboxylase, 79, 80, 85–91
 materials, 80–82
 retrograde tract-tracer Fluoro-Gold labeling of neurons,
 animals, 82, 83, 88
 periaqueductal gray neurons, 85
 rostral ventromedial medulla-spinal cord projecting neurons, 83–85, 88

In situ hybridization,

controls, 97, 104
 cresyl violet solution preparation, 97
 fixation, 97
 hybridization, 98, 99
 materials, 95, 96
 neural tissues, 95
 Nissl staining of tissue sections, 103, 104
 paraformaldehyde solution preparation, 96
 photographic emulsion coating of slides,
 development of slides, 102, 103
 dipping of slides, 101, 102
 emulsion preparation, 100, 101
 set-up, 99, 100
 prehybridization, 97
 probe labeling, 97, 98, 104, 105
 washing, 99, 105

Intrathecal injection,

advantages in opioid delivery, 217

catheterization,

catheter preparation, 218, 220
 insertion of catheter, 218–220
 surgery, 218, 220
 injection, 219–221
 materials, 217, 218, 220

K

Knockout mouse, opioid receptors,
 applications, 205
 blastocyst injection, 211
 breeding scheme and databases, 212, 214
 chimeric production and coat color strategy, 211
 embryonic stem cell manipulation,
 electroporation, 209, 213
 feeder cell preparation, 206–208
 freezing, 209
 homologous recombination screening,
 cell colony picking, 209, 210, 213, 215
 positive clone freezing and screening, 210, 211, 215
 mitomycin C treatment of fibroblasts, 208
 passage, 208, 209, 213
 thawing, 208
 materials for generation, 205, 206
 phenotype analysis, 213, 215
 tissue culture, 206, 213

L

LAAM, *see* Levo- α -acetylmethadol
 Levo- α -acetylmethadol (LAAM),
 maintenance therapy, 285, 286, 289, 290
 pharmacology, 287, 288, 292
 Lipofection, *see* Mammalian cell lines,
 opioid receptor expression
 Lofexidine, detoxification therapy, 286

Lumbar puncture,
 anesthesia, 220
 materials, 217, 218, 220
 needle insertion and injection, 220, 221

M

Maintenance therapy, *see*

 Buprenorphine; Levo- α -
 acetylmethadol; Methadone;
 Naltrexone

Mammalian cell lines, opioid receptor
 expression,

 cell line selection, 17, 18

 cloning into pcDNA3.1

 digestions, 20, 24, 25

 ligation, 20, 25

 plasmid isolation, 21, 25

 purification of digests, 20, 25

 transformation, 21, 25

 expression vector selection, 18

 materials, 19, 20, 24, 25

 opioid receptor types, 17

 stable transfection of Chinese

 hamster ovary cells,

 antibiotic concentration for

 selection, 22, 26

 cell culture, 22

 colony isolation, 23, 26

 DNA preparation, 22, 26

 lipofection, 22

 selection, 23

 transfection,

 stable versus transient, 19

 techniques, 18, 19

 transient transfection of Chinese

 hamster ovary cells,

 cell culture, 21, 25

 DEAE-dextran transfection, 21, 22,

 26

 DNA preparation, 21

 verification of expression,

 binding assay, 23, 24, 26

 Northern blot, 24

 reverse transcriptase-polymerase
 chain reaction, 24

 Western blot, 24

MAPK, *see* Mitogen-activated protein
 kinase

Methadone,

 clinical use, 277

 detoxification,

 adjunctive medications, 286

 precautions, 286, 292

 regimen, 291, 293

 development, 286

 maintenance therapy, 285, 289, 290

 pharmacology, 286, 287

Mitogen-activated protein kinase
 (MAPK),

 assay,

 gel electrophoresis, 44

 incubation conditions, 44, 45

 materials, 41

 radioactivity counting, 44

 sample preparation, 43, 44

 opioid receptor heterodimer

 signaling assay,

 principles, 173, 181

 Western blot of phosphorylated
 protein, 175

 opioid receptor signaling, 39, 157

 opioid tolerance role, 224

Morphine,

 clinical use, 276

 tolerance, *see* Tolerance, opioids

N

Naltrexone,

 development, 293

 maintenance therapy, 290, 291

- pharmacology, 288
- Neuropathic pain,
 - animal models,
 - behavioral determination of
 - hypersensitivity,
 - cold allodynia, 239
 - dynamic mechanical allodynia, 238
 - static mechanical allodynia, 237, 238, 241, 242
 - ligation and transfection of L5 spinal nerve, 236, 237, 241
 - materials, 234, 239, 240
 - overview, 233, 234
 - spared nerve injury model, 235, 236, 240, 241
 - definition, 272
 - features, 233, 272
 - pathophysiology, 272, 274
 - treatment, 274
- Northern blot, opioid receptor
 - expression verification in transfected cells, 24
- O**
- Oligomerization assays, opioid receptors,
 - bioluminescence resonance energy transfer,
 - data collection, 167–169
 - data presentation, 169, 170
 - fusion protein constructs, 167, 178
 - materials, 160
 - principles, 165–167, 177, 178
 - signal optimization, 179, 180
 - transfection, 167
 - cell culture, 158, 159
 - heterodimer characterization,
 - cell ligand binding studies, 172, 180
 - displacement assays, 170
 - displacement curves for cells and membranes, 171, 172
 - materials, 160
 - membrane ligand binding studies, 171
 - membrane preparation, 170, 171
 - saturation binding analysis, 170
 - transfection, 180
 - heterodimer signaling assays, cyclic AMP assay, materials, 161
 - principles, 173, 181
 - radioimmunoassay, 174
 - GTP γ S assay, agonist stimulation, 173, 174
 - materials, 161
 - membrane preparation, 173
 - principles, 173, 181
 - mitogen-activated protein kinase assay, principles, 173, 181
 - Western blot of phosphorylated protein, 175
 - overview, 172, 173
 - overview, 157, 158
 - trafficking effects of
 - heterodimerization, 175, 176, 181, 182
 - Western blot, blotting and analysis, 164, 165, 177
 - cell lysis, 159, 163
 - immunoprecipitation, 159, 160, 164, 176, 177
 - materials, 160
 - principles of assay, 161, 162
 - transient transfection, 159, 162, 163
- Oligonucleotide array,
 - data analysis, 143
 - principles, 142
 - uses, 142, 143
- Opioid receptors,
 - alternative splicing, *see* Splice variants, opioid receptors

- cloning, *see* Complementary DNA library screening, opioid receptors
- expression, *see* Mammalian cell lines, opioid receptor expression
- immunohistochemistry, *see* Immunohistochemistry, opioid receptors
- knockout mouse, *see* Knockout mouse, opioid receptors
- oligomerization, *see* Oligomerization assays, opioid receptors
- phosphorylation, *see* Phosphorylation, opioid receptors
- recombinant receptors, *see* Chimeric opioid receptors; Site-directed mutagenesis, opioid receptors
- signal transduction, *see* Adenylyl cyclase; Calcium/calmodulin-dependent protein kinase II; G protein-activated inwardly rectifying potassium channels; Mitogen-activated protein kinase; Protein kinase A; Protein kinase C
- transcript analysis, *see* Reverse transcriptase-polymerase chain reaction
- types, 17
- Oycodone, clinical use, 276
- P**
- PAG, *see* Periaqueductal gray
- Pain, *see also* Acute pain; Cancer pain; Chronic pain; Neuropathic pain, clinical evaluation, 268, 269, 280 definition, 267 self-report, 268 syndromes, 268, 279 transmission, 267
- PCR, *see* Polymerase chain reaction
- Periaqueductal gray (PAG), immunohistochemistry of opioid receptors, *see* Immunohistochemistry, opioid receptors
- opioid pain suppression, 79
- Phosphorylation, opioid receptors, cell labeling assay with, ³²P-orthophosphate, advantages, 48 cell culture, 49, 50 immunoprecipitation, 49 labeling reactions, 49, 50 materials, 48 overview, 47, 48 protein extraction, 49 desensitization role, 47
- PKA, *see* Protein kinase A
- PKC, *see* Protein kinase C
- Place conditioning, brain collection for analysis, 247, 248 cleaning of apparatus, 246, 247 conditioning, 247, 248 counterbalancing compartment assignments, 246–248 flexibility, 244 materials and apparatus, 245, 246 overview, 243–245 pairing sessions, 244 screening, 246 statistical analysis, 247 stimulus–stimulus associations, 243 surgery, 247, 248
- Polymerase chain reaction (PCR), *see also* Rapid amplification of complementary DNA ends; Reverse transcriptase-polymerase chain reaction, complementary DNA library screening, amplification reaction, 11, 12, 14

- full-length cDNA amplification, 12, 14, 15
- primer design, 11, 14
- product cloning and sequencing, 12, 14
- probe synthesis for library screening, 8, 13
- site-directed mutagenesis, point mutations, 194
- small insertions and deletions, 195, 196
- Protein kinase A (PKA),
 - assay,
 - gel electrophoresis, 43
 - incubation conditions, 43
 - materials, 40
 - tissue homogenization, 43, 45
 - opioid receptor signaling, 39
- Protein kinase C (PKC),
 - assay,
 - incubation conditions, 42, 45
 - lysate preparation, 42, 44
 - materials, 40, 44
 - radioactivity counting, 43, 45
 - opioid receptor signaling, 39
- Proteomics,
 - applications, 145
 - bioinformatics, 151, 152
 - capillary electrophoresis, 148, 149
 - data analysis, 151, 152
 - definition, 144
 - genomics comparison, 144, 145
 - high-performance liquid chromatography, 148, 149
 - mass spectrometry in protein identification, 150, 151
 - protein extraction, 145, 146
 - two-dimensional gel electrophoresis, imaging, 150
 - isoelectric separation, 147, 148
 - resolution, 147
 - size separation, 148
 - staining, 149, 150
- R**
- RACE, *see* Rapid amplification of complementary DNA ends
- Rapid amplification of complementary DNA ends (RACE), splice variants of opioid receptors, materials, 65, 66
- rapid amplification of complementary DNA 3'-end, 70, 74
- rapid amplification of complementary DNA 5'-end, cloning and sequencing
 - amplification products, 69, 70
- hybridization, 67
- ligation, 69
- polymerase chain reaction, 69, 74
- purification of DNA, 67, 69, 74
- reverse transcriptase reaction, 67, 73, 74
- Recombinant opioid receptors, *see* Chimeric opioid receptors; Site-directed mutagenesis, opioid receptors
- Reinforcement, *see* Self-administration model
- Reverse transcriptase-polymerase chain reaction (RT-PCR),
 - opioid receptor expression
 - verification in transfected cells, 24
 - single-cell studies, amplification reactions, 121, 133
 - cell harvesting, 118, 119, 132, 133
 - competitive polymerase chain reaction optimization, 121, 122, 133, 134
 - false negatives and positives, 131, 138

- gel electrophoresis and analysis, 122, 123
- glyceraldehyde-3-phosphate dehydrogenase in sensory neurons, 127, 129–131, 136–138
- in vitro transcription, 118
- materials, 110
- overview, 107, 108, 110, 111
- primer sequences, 119–121, 133
- quantitative analysis, amplification reaction, 123–125, 134
- reverse transcription reaction, 125, 126, 134–136
- random hexamer annealing, 119, 132, 133
- target sequence construction, glyceraldehyde-3-phosphate dehydrogenase, 114
- mutant clones, 112–114, 131, 132
- κ -1 opioid receptors, 116
- μ -1 opioid receptors, 116
- preprosomatostatin, 117, 118
- preprotachykinin β , 117, 118
- tissue culture, 112
- splice variants of opioid receptors, internal exon scanning, 71, 73, 74
- materials, 65, 66
- Rostral ventromedial medulla (RVM), immunohistochemistry of opioid receptors, *see* Immunohistochemistry, opioid receptors
- opioid pain suppression, 79
- RT-PCR, *see* Reverse transcriptase-polymerase chain reaction
- RVM, *see* Rostral ventromedial medulla
- S**
- SAGE, *see* Serial analysis of gene expression
- SCAM, *see* Substituted cysteine accessibility method
- Self-administration model, advantages, 252
- applications, 251, 252
- comparison with other opioid addiction models, 251
- data analysis, 262
- intracranial drug self administration, apparatus, 259
- rationale, 258, 259
- surgery, 259
- training, 259
- intravenous drug self administration, jugular catheter, fabrication, 254, 255
- implantation, 255, 256
- training, 256, 257
- materials, animals, 252
- computer and software, 253
- jugular catheters, 254
- operant chamber, 252, 253, 262
- reagents, 254
- spring arm connector assembly, 254
- syringe pump, 253
- operant food responding, 260
- phases, acquisition, 257
- extinction, 257
- maintenance, 257
- reinstatement, 257, 258
- reinforcement schedules, FR schedules, 260, 261
- PR schedules, 262
- second-order schedules, 261
- Serial analysis of gene expression (SAGE), comparison with microarray methods, 144

- principles, 143, 144
 - SHIRPA, knockout mouse phenotype assessment, 213, 215
 - Side effects, opioids, 270, 277
 - Site-directed mutagenesis, opioid receptors,
 - applications, 192, 194
 - materials, 186
 - polymerase chain reaction-based mutagenesis,
 - point mutations, 194
 - small insertions and deletions, 195, 196
 - substituted cysteine accessibility method,
 - applications, 197
 - mutant generation, 197
 - principles, 196
 - sulfhydryl-modifying reagents, ligand inhibition of reaction, 198
 - methanethiosulfonate sensitivity of wild-type protein, 196, 200
 - reaction with protein, 198, 200
 - types, 196
 - transfection, 198, 200
 - Somatostatin, single-cell reverse transcriptase-polymerase chain reaction of preprosomatostatin, 117, 118
 - Spared nerve injury model, *see* Neuropathic pain
 - Spinal cord dorsal horn, immunohistochemistry of opioid receptors, *see* Immunohistochemistry, opioid receptors
 - opioid pain suppression, 79
 - Spinal cord drug administration, *see* Intrathecal injection; Lumbar puncture
 - Splice variants, opioid receptors,
 - identification, approaches, 65
 - materials, 65, 66
 - rapid amplification of complementary DNA 3'-end, 70, 74
 - rapid amplification of complementary DNA 5'-end, cloning and sequencing
 - amplification products, 69, 70
 - hybridization, 67
 - ligation, 69
 - polymerase chain reaction, 69, 74
 - purification of DNA, 67, 69, 74
 - reverse transcriptase reaction, 67, 73, 74
 - reverse transcriptase-polymerase chain reaction, internal exon scanning, 71, 73, 74
 - overview, 65
 - Substituted cysteine accessibility method (SCAM), *see* Site-directed mutagenesis, opioid receptors
 - Subtractive hybridization,
 - comparison with microarray methods, 144
 - principles, 144
- T**
- Tachykinin, single-cell reverse transcriptase-polymerase chain reaction of preprotachykinin β , 117, 118
 - Tolerance, opioids,
 - adaptive responses, 223, 224
 - animal models, 224, 225
 - induction in rats, analgesia tests, animal handling, 228, 230
 - baseline latencies, 228

- morphine latencies and dose-response, 228
 - paw withdrawal, 227, 228
 - tail-flick, 227, 228
 - data analysis, 228, 230
 - implantation of morphine pellets, advantages and limitations, 226, 229, 230
 - anesthesia, 226
 - animals, 226, 230
 - surgery and implantation, 226, 227
 - injection of morphine solution, advantages and limitations, 226, 229, 230
 - anesthesia, 227
 - animals, 227
 - regimen of injections, 227, 230
 - materials, 225
 - neonates, 225
 - Transfection, *see* Mammalian cell lines, opioid receptor expression; Oligomerization assays, opioid receptors
 - Transmembrane domains, opioid receptors, 185
 - Two-dimensional gel electrophoresis, *see* Proteomics
- U**
- Ultrarapid opiate detoxification (UROD), protocols and efficacy, 291, 293
- UROD, *see* Ultrarapid opiate detoxification
- W**
- Weaver* mouse, behavioral analysis, 61
 - breeding, 60, 61
 - genotyping, 60
 - G protein-activated inwardly rectifying potassium channel missense mutation, 59
 - overview, 54, 59
- Western blot, mitogen-activated protein kinase activation assay, 175
- oligomerization assay for opioid receptors, blotting and analysis, 164, 165, 177
 - cell lysis, 159, 163
 - immunoprecipitation, 159, 160, 164, 176, 177
 - materials, 160
 - principles of assay, 161, 162
 - transient transfection, 159, 162, 163
 - opioid receptor expression verification in transfected cells, 24
- X**
- Xenopus* oocyte, *see* G protein-activated inwardly rectifying potassium channels